Novartis AG vs ProShares UltraPro Short QQQ ETF — how do they compare? Novartis AG trades at $152.84 (market cap $295.37B), while ProShares UltraPro Short QQQ ETF trades at $37.26. The key difference: Novartis AG pays a 3.07% dividend while ProShares UltraPro Short QQQ ETF pays none, and Novartis AG is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| NVS | SQQQ | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $168.62 | $92.95 |
52-Week Low | $119.31 | $36.31 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $37.15, down 1.56% on the day. Technical indicators are bearish overall, with moving averages signaling selling pressure, though oscillators are neutral. The ETF is designed for short-term tactical use, not long-term holding, due to daily resets that erode value over time.
The outlook for SQQQ is highly speculative, offering potential gains if the Nasdaq-100 declines, but risks are severe, including rapid decay from leverage and volatility decay. It may serve as a hedge for QQQ holdings but is unsuitable as a standalone investment given its long-term performance history of significant losses.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →